229 related articles for article (PubMed ID: 25621824)
21. Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase.
Damgaard D; Bjørn ME; Jensen PØ; Nielsen CH
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):1203-1208. PubMed ID: 28933232
[TBL] [Abstract][Full Text] [Related]
22. Structural basis for Ca(2+)-induced activation of human PAD4.
Arita K; Hashimoto H; Shimizu T; Nakashima K; Yamada M; Sato M
Nat Struct Mol Biol; 2004 Aug; 11(8):777-83. PubMed ID: 15247907
[TBL] [Abstract][Full Text] [Related]
23. Proteomics implicates peptidyl arginine deiminase 2 and optic nerve citrullination in glaucoma pathogenesis.
Bhattacharya SK; Crabb JS; Bonilha VL; Gu X; Takahara H; Crabb JW
Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2508-14. PubMed ID: 16723463
[TBL] [Abstract][Full Text] [Related]
24. Functional roles of the non-catalytic calcium-binding sites in the N-terminal domain of human peptidylarginine deiminase 4.
Liu YL; Tsai IC; Chang CW; Liao YF; Liu GY; Hung HC
PLoS One; 2013; 8(1):e51660. PubMed ID: 23382808
[TBL] [Abstract][Full Text] [Related]
25. Structural characterization of human peptidyl-arginine deiminase type III by X-ray crystallography.
Rechiche O; Lee TV; Lott JS
Acta Crystallogr F Struct Biol Commun; 2021 Oct; 77(Pt 10):334-340. PubMed ID: 34605437
[TBL] [Abstract][Full Text] [Related]
26. Inhibitors of protein arginine deiminases and their efficacy in animal models of multiple sclerosis.
Sarswat A; Wasilewski E; Chakka SK; Bello AM; Caprariello AV; Muthuramu CM; Stys PK; Dunn SE; Kotra LP
Bioorg Med Chem; 2017 May; 25(9):2643-2656. PubMed ID: 28341402
[TBL] [Abstract][Full Text] [Related]
27. Involvement of peptidylarginine deiminase-mediated post-translational citrullination in pathogenesis of sporadic Creutzfeldt-Jakob disease.
Jang B; Jin JK; Jeon YC; Cho HJ; Ishigami A; Choi KC; Carp RI; Maruyama N; Kim YS; Choi EK
Acta Neuropathol; 2010 Feb; 119(2):199-210. PubMed ID: 20013286
[TBL] [Abstract][Full Text] [Related]
28. Peptidylarginine deiminase 2 is required for tumor necrosis factor alpha-induced citrullination and arthritis, but not neutrophil extracellular trap formation.
Bawadekar M; Shim D; Johnson CJ; Warner TF; Rebernick R; Damgaard D; Nielsen CH; Pruijn GJM; Nett JE; Shelef MA
J Autoimmun; 2017 Jun; 80():39-47. PubMed ID: 28188029
[TBL] [Abstract][Full Text] [Related]
29. Modulation of peptidyl arginine deiminase 2 and implication for neurodegeneration.
Bhattacharya SK; Bhat MB; Takahara H
Curr Eye Res; 2006 Dec; 31(12):1063-71. PubMed ID: 17169845
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of human peptidylarginine deiminase 2 (hPAD2)--reduction of Ca2+ dependence by phospholipids and assessment of proposed inhibition by paclitaxel side chains.
Musse AA; Polverini E; Raijmakers R; Harauz G
Biochem Cell Biol; 2008 Oct; 86(5):437-47. PubMed ID: 18923545
[TBL] [Abstract][Full Text] [Related]
31. Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation.
Dreyton CJ; Anderson ED; Subramanian V; Boger DL; Thompson PR
Bioorg Med Chem; 2014 Feb; 22(4):1362-9. PubMed ID: 24440480
[TBL] [Abstract][Full Text] [Related]
32. Increased levels of peptidylarginine deiminase 2 in synovial fluid from anti-CCP-positive rheumatoid arthritis patients: Association with disease activity and inflammatory markers.
Damgaard D; Senolt L; Nielsen CH
Rheumatology (Oxford); 2016 May; 55(5):918-27. PubMed ID: 26880831
[TBL] [Abstract][Full Text] [Related]
33. Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease.
Ishigami A; Ohsawa T; Hiratsuka M; Taguchi H; Kobayashi S; Saito Y; Murayama S; Asaga H; Toda T; Kimura N; Maruyama N
J Neurosci Res; 2005 Apr; 80(1):120-8. PubMed ID: 15704193
[TBL] [Abstract][Full Text] [Related]
34. Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro.
Raijmakers R; Zendman AJ; Egberts WV; Vossenaar ER; Raats J; Soede-Huijbregts C; Rutjes FP; van Veelen PA; Drijfhout JW; Pruijn GJ
J Mol Biol; 2007 Apr; 367(4):1118-29. PubMed ID: 17303166
[TBL] [Abstract][Full Text] [Related]
35. Molecular Mechanism of Protein Arginine Deiminase 2: A Study Involving Multiple Microsecond Long Molecular Dynamics Simulations.
Cicek E; Monard G; Sungur FA
Biochemistry; 2022 Jul; 61(13):1286-1297. PubMed ID: 35737372
[TBL] [Abstract][Full Text] [Related]
36. Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential.
Jones JE; Causey CP; Knuckley B; Slack-Noyes JL; Thompson PR
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):616-27. PubMed ID: 19736621
[TBL] [Abstract][Full Text] [Related]
37. Microglial expression of peptidylarginine deiminase 2 in the prenatal rat brain.
Asaga H; Ishigami A
Cell Mol Biol Lett; 2007; 12(4):536-44. PubMed ID: 17579814
[TBL] [Abstract][Full Text] [Related]
38. The human peptidylarginine deiminases type 2 and type 4 have distinct substrate specificities.
Assohou-Luty C; Raijmakers R; Benckhuijsen WE; Stammen-Vogelzangs J; de Ru A; van Veelen PA; Franken KL; Drijfhout JW; Pruijn GJ
Biochim Biophys Acta; 2014 Apr; 1844(4):829-36. PubMed ID: 24594197
[TBL] [Abstract][Full Text] [Related]
39. Photochemical Control of Protein Arginine Deiminase (PAD) Activity.
Mondal S; Parelkar SS; Nagar M; Thompson PR
ACS Chem Biol; 2018 Apr; 13(4):1057-1065. PubMed ID: 29517899
[TBL] [Abstract][Full Text] [Related]
40. Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation.
Knuckley B; Causey CP; Pellechia PJ; Cook PF; Thompson PR
Chembiochem; 2010 Jan; 11(2):161-5. PubMed ID: 20014086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
